London, UK, and Atlanta, GA, 10 December 2007 - Positive preclinical data supporting Antisoma’s ongoing phase II trial of AS1411 in AML (acute myeloid leukaemia) were presented this weekend at the American Society of Hematology (ASH) meeting in Atlanta, Georgia. Researchers from the Medical University of South Carolina showed that AS1411 killed AML cells with high potency and associated this with down-regulation of the apoptosis-blocking protein Bcl-2. Apoptosis is the programmed cell death pathway that normally removes malfunctioning cells.
